ENLIVEN THERAPEUTICS, INC. Increase Decrease In Operating Lease Liability
ENLIVEN THERAPEUTICS, INC. (ELVN) reported Increase Decrease In Operating Lease Liability of -$226.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInOperatingLeaseLiability · last filed 2026-08-05
- ENLIVEN THERAPEUTICS, INC. increase decrease in operating lease liability for the quarter ending 2026-06-30 was -$129.00K.
- ENLIVEN THERAPEUTICS, INC. increase decrease in operating lease liability for the quarter ending 2026-03-31 was -$97.00K.
- ENLIVEN THERAPEUTICS, INC. increase decrease in operating lease liability for the quarter ending 2025-12-31 was -$91.00K.
- ENLIVEN THERAPEUTICS, INC. increase decrease in operating lease liability for the quarter ending 2025-09-30 was -$90.00K.
- ENLIVEN THERAPEUTICS, INC. increase decrease in operating lease liability for fiscal 2025 was -$337.00K.
- ENLIVEN THERAPEUTICS, INC. increase decrease in operating lease liability for fiscal 2024 was -$335.00K.
- ENLIVEN THERAPEUTICS, INC. increase decrease in operating lease liability for fiscal 2023 was -$310.00K, a 7850.00% decline from fiscal 2022.
- ENLIVEN THERAPEUTICS, INC. increase decrease in operating lease liability for fiscal 2022 was $4.00K.
| Period end | Increase Decrease In Operating Lease Liability 3 month | Increase Decrease In Operating Lease Liability 6 month | Increase Decrease In Operating Lease Liability 9 month | Increase Decrease In Operating Lease Liability 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$129.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | -$226.00K 10-Q · filed 2026-08-05 | -$317.00K derived: sum of 3 quarters · filed 2026-08-05 | -$407.00K derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | -$97.00K 10-Q · filed 2026-05-07 | -$188.00K derived: sum of 2 quarters · filed 2026-05-07 | -$278.00K derived: sum of 3 quarters · filed 2026-05-07 | -$365.00K derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-12-31 | -$91.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-03 | -$181.00K derived: sum of 2 quarters · filed 2026-03-03 | -$268.00K derived: sum of 3 quarters · filed 2026-08-05 | -$337.00K 10-K · filed 2026-03-03 |
| 2025-09-30 | -$90.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | -$177.00K derived: sum of 2 quarters · filed 2026-08-05 | -$246.00K 10-Q · filed 2025-11-12 | -$331.00K derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-06-30 | -$87.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | -$156.00K 10-Q · filed 2026-08-05 | -$241.00K derived: sum of 3 quarters · filed 2026-08-05 | -$325.00K derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-03-31 | -$69.00K 10-Q · filed 2026-05-07 | -$154.00K derived: sum of 2 quarters · filed 2026-05-07 | -$238.00K derived: sum of 3 quarters · filed 2026-05-07 | -$321.00K derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | -$85.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-03 | -$169.00K derived: sum of 2 quarters · filed 2026-03-03 | -$252.00K derived: sum of 3 quarters · filed 2026-03-03 | -$335.00K 10-K · filed 2026-03-03 |
| 2024-09-30 | -$84.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | -$167.00K derived: sum of 2 quarters · filed 2025-11-12 | -$250.00K 10-Q · filed 2025-11-12 | -$329.00K derived: sum of 4 quarters · filed 2025-11-12 |
| 2024-06-30 | -$83.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-13 | -$166.00K 10-Q · filed 2025-08-13 | -$245.00K derived: sum of 3 quarters · filed 2025-08-13 | -$474.00K derived: sum of 4 quarters · filed 2025-08-13 |
| 2024-03-31 | -$83.00K 10-Q · filed 2025-05-14 | -$162.00K derived: sum of 2 quarters · filed 2025-05-14 | -$391.00K derived: sum of 3 quarters · filed 2025-05-14 | -$392.00K derived: sum of 4 quarters · filed 2025-05-14 |
| 2023-12-31 | -$79.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-13 | -$308.00K derived: sum of 2 quarters · filed 2025-03-13 | -$309.00K derived: sum of 3 quarters · filed 2025-03-13 | -$310.00K 10-K · filed 2025-03-13 |
| 2023-09-30 | -$229.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-13 | -$230.00K derived: sum of 2 quarters · filed 2024-11-13 | -$231.00K 10-Q · filed 2024-11-13 | -$230.00K derived: sum of 4 quarters · filed 2024-11-13 |
| 2023-06-30 | -$1.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-13 | -$2.00K 10-Q · filed 2024-08-13 | -$1.00K derived: sum of 3 quarters · filed 2024-08-13 | |
| 2023-03-31 | -$1.00K 10-Q · filed 2024-05-14 | $0.00 derived: sum of 2 quarters · filed 2024-05-14 | ||
| 2022-12-31 | $1.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-14 | $4.00K 10-K · filed 2024-03-14 | ||
| 2022-09-30 | $3.00K 10-Q · filed 2023-11-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| Arcus Biosciences, Inc. (RCUS) | United States | $3.188B | -8.52 |
| Dyne Therapeutics, Inc. (DYN) | United States | $3.084B | -7.09 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| PRECIGEN, INC. (PGEN) | United States | $2.757B | -12.94 |
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 |